Description
Key facts
Detection method:Colorimetric,
Sample types:Heparin Plasma, Citrate plasma, Cell culture supernatant, Serum, EDTA Plasma,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 59 pg/mL,
Range:0.313 - 20 ng/mL,
Assay time:1h 30m,
Assay Platform:Microplate
Product details:
Human Apolipoprotein AI ELISA Kit ab189576 is a rapid single-wash 90-min Sandwich ELISA to measure Human Apolipoprotein AI in cell culture supernatant, citrate plasma, EDTA plasma, heparin plasma, serum. This SimpleStep sensitivity is 59 pg/mL.
How the assay works
Human Apolipoprotein AI SimpleStep ELISA
employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA
plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA
protocol summary in the image section for further details.
Assay Specificity
Our SimpleStep ELISA
kits use recombinant monoclonal antibodies rigorously validated to ensure the highest level of consistency and reproducibility, improved sensitivity and specificity and ease of scalability and security of supply.
Please refer to our protocol booklet for more details.
Human Apolipoprotein AI ELISA Kit ab189576 protocol summary
1. Mix: add samples/standards to the wells together with the capture and detector antibody cocktail. Incubate 1 hr at room temperature
2. Wash
3. Add TMB development solution - incubate for 10 min
4. Add Stop solution
5. Read the results on a plate reader at 450 nm
Apolipoprotein AI (ApoA1) is secreted by the liver and small intestine and is a major protein of plasma HDL (high density lipoprotein). APOA-I participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). Defects in APOA1I are associated with several diseases associated with low HDL levels (HDLD1 and HDLD2) and amyloidosis (AMYL8).
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A-I (ApoA-I) is a major component of high-density lipoprotein (HDL) particles often referred to as 'good cholesterol'. It has a molecular mass of approximately 28 kDa. ApoA-I is mainly expressed in the liver and intestine. It plays a mechanical role in the reverse transport of cholesterol acting to facilitate the efflux of cholesterol from tissues to the liver for excretion. Its alternative names include ApoAI ApoA1 and a component of the AI kits used for measuring this protein.
Biological function summary
ApoA-I functions in cholesterol homeostasis and inflammation. It is a structural component of the HDL complex that mobilizes cholesterol. ApoA-I acts as an activator of the enzyme lecithin-cholesterol acyltransferase (LCAT) which is essential for the maturation of HDL particles. This maturation is necessary for effective cholesterol transport and clearance. ApoA-I's ability to stabilize HDL particles and enhance their functionality makes it significant for maintaining lipid balance and cellular homeostasis.
Pathways
The interaction of ApoA-I with HDL formation and function marks its role in lipid metabolism pathways. Its participation in the reverse cholesterol transport pathway highlights its influence on cardiovascular health. ApoA-I also interacts with other proteins like ApoA-II and paraoxonase-1 which further influence lipid metabolism and antioxidant activities. Understanding these relationships helps elucidate the dynamics of cholesterol removal from the bloodstream.
Disturbances in ApoA-I levels correlate with cardiovascular disease and atherosclerosis. Deficiency or dysfunction in ApoA-I can impair HDL function leading to poor cholesterol removal and buildup within arteries. It is also connected to amyloidosis where misfolded ApoA-I forms deposits in tissues. Understanding these pathological conditions helps researchers target ApoA-I in therapeutic strategies to mitigate disease progression often studying it alongside proteins like ApoB which is associated with low-density lipoprotein (LDL) particles.
